SAN ANTONIO – Know your patient’s number: Dr. Edith A. Perez of the Mayo Clinic in Jacksonville, Fla., explains in a video interview how the level of stromal tumor infiltrating lymphocytes (TILs) in women with early-stage, HER2+ breast cancer may be useful in identifying a subset who might potentially do quite well with chemotherapy alone.